Danaher Corporation (DHR)
NYSE: DHR · Real-Time Price · USD
238.36
-3.54 (-1.46%)
Jan 17, 2025, 4:00 PM EST - Market closed
Danaher Employees
Danaher had 63,000 employees as of December 31, 2023. The number of employees decreased by 18,000 or -22.22% compared to the previous year.
Employees
63,000
Change (1Y)
-18,000
Growth (1Y)
-22.22%
Revenue / Employee
$376,857
Profits / Employee
$61,778
Market Cap
172.16B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 63,000 | -18,000 | -22.22% |
Dec 31, 2022 | 81,000 | 1,000 | 1.25% |
Dec 31, 2021 | 80,000 | 11,000 | 15.94% |
Dec 31, 2020 | 69,000 | 9,000 | 15.00% |
Dec 31, 2019 | 60,000 | -11,000 | -15.49% |
Dec 31, 2018 | 71,000 | 4,000 | 5.97% |
Dec 31, 2017 | 67,000 | 5,000 | 8.06% |
Dec 31, 2016 | 62,000 | -19,000 | -23.46% |
Dec 31, 2015 | 81,000 | 10,000 | 14.08% |
Dec 31, 2014 | 71,000 | 5,000 | 7.58% |
Dec 31, 2013 | 66,000 | 3,000 | 4.76% |
Dec 31, 2012 | 63,000 | 4,000 | 6.78% |
Dec 31, 2011 | 59,000 | 10,800 | 22.41% |
Dec 31, 2010 | 48,200 | 1,600 | 3.43% |
Dec 31, 2009 | 46,600 | -3,700 | -7.36% |
Dec 31, 2008 | 50,300 | 300 | 0.60% |
Dec 31, 2007 | 50,000 | 5,000 | 11.11% |
Dec 31, 2006 | 45,000 | 5,000 | 12.50% |
Dec 31, 2005 | 40,000 | 5,000 | 14.29% |
Dec 31, 2004 | 35,000 | 5,000 | 16.67% |
Dec 31, 2003 | 30,000 | 1,000 | 3.45% |
Dec 31, 2002 | 29,000 | 6,000 | 26.09% |
Dec 31, 2001 | 23,000 | -1,000 | -4.17% |
Dec 31, 2000 | 24,000 | 5,000 | 26.32% |
Dec 31, 1999 | 19,000 | 1,000 | 5.56% |
Dec 31, 1998 | 18,000 | 4,800 | 36.36% |
Dec 31, 1997 | 13,200 | 1,600 | 13.79% |
Dec 31, 1996 | 11,600 | 1,100 | 10.48% |
Dec 31, 1995 | 10,500 | 540 | 5.42% |
Dec 31, 1994 | 9,960 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
DHR News
- 1 hour ago - Aldevron Unveils Next-Generation Alchemy™ Cell-Free DNA Technology for Research Grade Applications - Business Wire
- 5 days ago - Danaher: Transition Year Recap - Seeking Alpha
- 5 days ago - The Near-Perfect Dividend Portfolio With 10 Sleep-Well-At-Night Gems - Seeking Alpha
- 6 days ago - Beckman Coulter Introduces Cutting-Edge Research Use Only Assays for Neurodegenerative Disease Research - PRNewsWire
- 6 days ago - Danaher Corporation (DHR) 43rd Annual J.P. Morgan Healthcare Conference (Transcript) - Seeking Alpha
- 7 days ago - Danaher CEO to Comment on Financial Performance - PRNewsWire
- 7 days ago - Using SA's Stock Screener: Sell 6 Overvalued Blue Chips, With Stagnating Growth - Seeking Alpha
- 11 days ago - Danaher Announces Investment Partnership in Innovaccer Inc. - PRNewsWire